NCT04648137View on ClinicalTrials.gov

Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Diabetes Insipidus
Interventions
DIAGNOSTIC_TEST

study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)

single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.

DIAGNOSTIC_TEST

Control intervention: Placebo

Identical placebo (only mannitol) capsules

Trial Locations (1)

4031

University Hospital Basel, Endocrinology, Diabetes and Metabolism, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04648137 - Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls | Biotech Hunter | Biotech Hunter